FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, particularly to an antibody to CA-XII (carbonic anhydrase 12) or an antigen-binding fragment specifically binding to CA-XII, as well as to a pharmaceutical composition for preventing, ameliorating or treating a solid malignant growth expressing CA-XII containing it. Also disclosed is a nucleic acid molecule encoding said antibody or its antigen-binding fragment, as well as an expression vector and a host cell containing it. Invention also relates to a method for detecting a solid malignant growth expressing CA-XII, comprising using said antibody or its antigen-binding fragment specifically binding to CA-XII.
EFFECT: invention enables effective prevention, alleviation or treatment of a solid malignant growth expressing CA-XII.
36 cl, 36 dwg, 20 tbl, 19 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CD43 ANTIBODIES AND USE THEREOF FOR TREATING CANCER | 2016 |
|
RU2694903C1 |
| ANTIBODIES TO HUMAN INTERLEUKIN-2 AND THEIR APPLICATION | 2018 |
|
RU2745451C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER | 2014 |
|
RU2678138C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING MALIGNANT GROWTH | 2012 |
|
RU2595400C2 |
| PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND PREVENTION | 2012 |
|
RU2641260C2 |
| ANTI-PD-L1 ANTIBODY AND ITS USE | 2020 |
|
RU2783685C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING MALIGNANT GROWTH | 2012 |
|
RU2610428C2 |
| PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION | 2012 |
|
RU2611197C2 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THIOREDOXIN-1 AND ITS USE | 2016 |
|
RU2747929C2 |
